Conversely, the CBBBP peptide alone demonstrated a less marked effect, indicating that the primary therapeutic benefits are attributable to the DSIP component
Summary: Retatrutide, an investigational GLP-1/GIP/glucagon triple agonist, most commonly causes gastrointestinal side effects, and no direct human fertility data currently exist, though indirect reproductive benefits via weight loss are plausible
A 2011 study published in Physiology & Behavior demonstrated that GLP-1 receptor agonists suppress water intake even when appetite isn't affected
Rhonda Patrick: Well I had shifted to supplementation with sulforaphane
Epidemiological studies indicate that diabetes prevalence increased from 3.0% to 4.1%, while obesity rates rose from 32.7% to 40.9% between 2009 and 2020, according to the Journal of the American Medical Association